U-104

Catalog No.S2866 Synonyms: MST-104, NSC 213841, SLC-0111, WBI-5111

For research use only.

U-104 (MST-104, NSC 213841, SLC-0111, WBI-5111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki of 45.1 nM and 4.5 nM, respectively, very low inhibition for CA I and CA II.

U-104 Chemical Structure

CAS No. 178606-66-1

Selleck's U-104 has been cited by 7 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective Carbonic Anhydrase Inhibitors

Other Carbonic Anhydrase Products

Biological Activity

Description U-104 (MST-104, NSC 213841, SLC-0111, WBI-5111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki of 45.1 nM and 4.5 nM, respectively, very low inhibition for CA I and CA II.
Targets
CAXII [1]
(Cell-free assay)
CAIX [1]
(Cell-free assay)
4.5 nM(Ki) 45.1 nM(Ki)
In vitro

U-104 (50  μM) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50  μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells. [2] U-104 possesses aromatic groups at the second nitrogen ureido group. [3]

In vivo U-104 (38 mg/kg) inhibits primary tumor growth in the mice implanted orthotopically with MDA-MB-231 LM2-4Luc+ cells. U-104 (19 mg/kg) inhibits metastases formation in the 4T1 experimental metastasis mice model. [1] U-104 (38 mg/kg) significantly delay primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells. U-104 (5 mg/mL, oral gavage) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells. [2]

Protocol (from reference)

Animal Research:[2]
  • Animal Models: Balb/c mice orthotopically implanted with 4T1 cells.
  • Dosages: 5 mg/mL
  • Administration: Oral gavage

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 309.32
Formula

C13H12FN3O3S

CAS No. 178606-66-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)S(=O)(=O)N)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03450018 Suspended Drug: SLC-0111|Drug: Gemcitabine Injection Metastatic Pancreatic Ductal Adenocarcinoma British Columbia Cancer Agency|Welichem Biotech Inc.|Canadian Cancer Society (CCS) January 10 2019 Phase 1|Phase 2
NCT02215850 Completed Drug: SLC-0111 Solid Tumours Welichem Biotech Inc.|Ozmosis Research Inc. October 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy U-104 | U-104 supplier | purchase U-104 | U-104 cost | U-104 manufacturer | order U-104 | U-104 distributor